glp-1 treatment for newly diagnosed diabetes guidelines Effect of combination with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study MCT2D | The Benefits of
Description
Less common but potentially serious risks may include pancreatitis (inflammation of the pancreas), gallbladder problems, kidney damage, allergic reactions, and thyroid tumors
Zheng, H., Ryzhov, I
In addition, first oral GLP-1 receptor agonist (oral semaglutide) was recently approved (18)
Ideal Candidates GLP-1 medications are typically prescribed for individuals with a BMI of 30 or higher or those with a BMI of 27 or higher with weight-related conditions such as type 2 diabetes or hypertension
Basic research in cardiology
